A Phase II, Double-Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination With Pemetrexed (Alimta) vs. Pemetrexed Alone in Patients With Non-Small Cell Lung Cancer Who Have Failed One Prior Platinum-Based Chemotherapy Regimen.

Trial Profile

A Phase II, Double-Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination With Pemetrexed (Alimta) vs. Pemetrexed Alone in Patients With Non-Small Cell Lung Cancer Who Have Failed One Prior Platinum-Based Chemotherapy Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Pemetrexed; Zibotentan
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2011 Results published in Cancer Chemotherapy and Pharmacology.
    • 19 Mar 2010 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
    • 19 Mar 2010 Actual patient number (66) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top